Peri-operative management of a patient with hereditary angioedema undergoing laparoscopic cholecystectomy

Anaesthesia

Volumn 65, Issue 1, 2010, Pages 74-77

  Spyridonidou, Aliki ^a   Iatrou, C ^a   Alexoudis, A ^a   Vogiatzaki, T ^a   Polychronidis, A ^a   Simopoulos, C ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; CISATRACURIUM; COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; DILTIAZEM; NEOSTIGMINE; REMIFENTANIL; SEVOFLURANE;

ADULT; ANAMNESIS; ANESTHESIST; ANGIONEUROTIC EDEMA; ARTICLE; CASE REPORT; CHOLECYSTECTOMY; FEMALE; HUMAN; INTENSIVE CARE UNIT; PERIOPERATIVE PERIOD;

ADULT; ANESTHESIA, GENERAL; ANGIOEDEMAS, HEREDITARY; CHOLECYSTECTOMY, LAPAROSCOPIC; CHOLELITHIASIS; FEMALE; HUMANS; PERIOPERATIVE CARE;

EID: 71949108640     PISSN: 00032409     EISSN: 13652044     Source Type: Journal    
DOI: 10.1111/j.1365-2044.2009.06130.x     Document Type: Article

References (32)

1. Samsoon GT, Young JB. Difficult tracheal intubation: a retrospective study. Anaesthesia 1987; 42: 487-490
2. Wilson ME. Predicting difficult intubation. British Journal of Anaesthesia 1993; 71: 333-334
3. Savva D. Prediction of difficult tracheal intubation. British Journal of Anaesthesia 1994; 73: 149-153
4. Frerk SM. Predicting difficult intubation. Anaesthesia 1991; 46: 1005-1008
5. Bond A, Nussey A. Clinical prediction of difficult intubation. Anaesthesia and Intensive Care 1993; 21: 358-360
6. Temino VM, Peebles RS. The spectrum and treatment of angioedema. American Journal of Medicine 2008; 121: 282-286
7. Cugno M, Zanichelli A, Foieni F, Caccia S, Cicardi M. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends in Molecular Medicine 2009; 15: 69-78.
8. Davis AE. Mechanism of angioedema in first complement component inhibitor deficiency. Immunology and Allergy Clinics of North America 2006; 26: 633-651
9. Gompels MM, Lock RJ, Abinum M, et al. C1 inhibitor deficiency: consensus document. Clinical and Experimental Immunology 2005; 139: 379-394
10. Roche O, Blanch A, Caballero T, Sastre N, Callejo D, Lopez-Trascasa M. Angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Annals of Allergy, Asthma and Immunology 2005; 94: 498-503. (Pubitemid 40547939)
11. Bork K, Barnstedt SE, Kock P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000; 356: 213-217 (Pubitemid 30446977)
12. Bork K. Hereditary angioedema with normal C1 inhibitor activity including hereditary angioedema with coagulation factor XII gene mutations. Immunology and Allergy Clinics of North America 2006; 26: 709-724 (Pubitemid 44666307)
13. Visy B, Fust G, Bygum A, et al. Helicobacter pylori infection as a triggering factor of attacks in patients with hereditary angioedema. Helicobacter 2007; 12: 251-257 (Pubitemid 46701095)
14. Bork K, Siedlecki K, Bosch S, Schopf RE, Kreuz W. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clinic Proceedings 2000; 75: 349-354 (Pubitemid 30187107)
15. Bork K, Hardt J, Schicketanz KH, Ressel N. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Archives of Internal Medicine 2003; 163: 1229-1235 (Pubitemid 36613077)
16. Agostini A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992; 71: 206-215
17. Frank MM. Hereditary angioedema. Journal of Allergy and Clinical Immunology 2008; 121: S398-401.
18. Zuraw BL. Hereditary angioedema. New England Journal of Medicine 2008; 359: 1027-1036
19. Agostini A, Aygoren-Pursun E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. Journal of Allergy and Clinical Immunology 2004; 114: S151-31.
20. Bowen T, Cicardi M, Farkas H, et al. Canadian 2003 international consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema. Journal of Allergy and Clinical Immunology 2004; 114: 629-637
21. Hallberg P, Brenning G. Angioedema induced by tramadola potentially life-threatening condition. European Journal of Clinical Pharmacology 2005; 60: 901-903 (Pubitemid 40386162)
22. Byrd JB, Adam A, Browb NJ. Angiotensin-converting enzyme inhibitor-associated angioedema. Immunology and Allergy Clinics of North America 2006; 26: 725-737
23. Cocchio C, Marzella N. Cinryze, a human plasma-derived C1 esterase inhibitor for prophylaxis of Hereditary Angioedema. P and T: A Peer-Reviewed Journal for Formulary Management 2009; 34: 293-328.
24. Jensen NF, Weiler JM. C1 esterase inhibitor deficienty, airway compromise, and anesthesia. Anesthesia and Analgesia 1998; 87: 480-488
25. Zuraw BL. Current and future therapy for hereditary angioedema. Clinical Immunology 2005; 114: 10-16. (Pubitemid 39642785)
26. Longhurst HJ. Emergency treatment of acute attacks in hereditary angioedema due to C1 inhibitor deficiency: what is the evidence? International Journal of Clinical Practice 2005; 59: 597-599
27. Bork K, Barnstedt SE. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Archives of Internal Medicine 2001; 161: 714-718 (Pubitemid 32200225)
28. Cox M, Holdcroft A. Hereditary angioneurotic oedema: current management in pregnancy. Anaesthesia 1995; 50: 547-549
29. Choi G, Soeters MR, Farkas H. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion 2007; 47: 1028-1032 (Pubitemid 46802091)
30. Prematta M, Gibbs JG, Pratt EL, Stoughton TR, Craig TJ. Fresh frozen plasma for the treatment of hereditary angioedema. Annals of Allergy, Asthma and Immunology 2007; 98: 383-388 (Pubitemid 46582131)
31. Crude NL, Newby DE. Therapeutic potential of icatibant (HOE-140, JE-049). Expert Opinion of Pharmacotherapy 2008; 9: 2383-2390
32. Scheider L, Lumry W, Vegh A, Williams AH, Schmalbach T. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. Journal of Allergy and Clinical Immunology 2007; 120: 416-422